Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.
    Difference
    0.0%
    Check dated 2024-10-03T05:04:40.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.
    Difference
    0.6%
    Check dated 2024-09-25T22:44:40.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    ClinicalTrials.gov is addressing delays in displaying study record information, and the website has been updated to version 2.10.5, replacing the previous version 2.10.3.
    Difference
    0.5%
    Check dated 2024-09-18T16:49:20.000Z thumbnail image
  5. Check
    31 days ago
    No Change Detected
  6. Check
    38 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.2 to 2.10.3, indicating a new release.
    Difference
    0.0%
    Check dated 2024-09-04T05:18:20.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The website has been updated from version v2.10.0 to v2.10.2.
    Difference
    0.0%
    Check dated 2024-08-13T23:44:45.000Z thumbnail image
  8. Check
    78 days ago
    Change Detected
    Summary
    A new resource titled 'Helpful Links Provided by Andrea Ardizzoni' has been added, featuring information on Cabozantinib (XL184), highlighting its role as a novel MET and VEGFR2 inhibitor that suppresses metastasis, angiogenesis, and tumor growth.
    Difference
    0.6%
    Check dated 2024-07-25T17:17:37.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.